Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

Bullboard (TSX:CSCI)

View:
Post by prophetoffactzon Aug 15, 2024 7:54pm

Copilot: Insulin Tolerance Test(ITT) vs. CSCI's Test:

Insulin Tolerance Test (ITT) Procedure: ITT involves administering insulin to induce hypoglycemia (low blood sugar). This triggers the release of growth hormone, which is then measured ...more  
Post by prophetoffactzon Aug 15, 2024 7:59am

"Live long and prosper" oat chewy

CSCI could get Jennifer Aniston to use her Aveeno association to sell its oat chewy products. Aveeno inside! It could get the world's oldest family who swears by oats to endorse the product. CSCI ...more  
Comment by prophetoffactzon Aug 14, 2024 2:19pm

RE:Concerns with Quarterly

Hopeforthebest: "Reduced sales totals for PGX". LOL! 
Post by Hopeforthebeston Aug 14, 2024 11:34am

Concerns with Quarterly

Only had the opportunity to briefly review the quarterly report and a few things really concerned me. The amount of cash the merged company is eating through Reduced sales totals for PGX Cost of ...more  
Post by prophetoffactzon Aug 14, 2024 11:31am

Pediatric Diagnostic Test

The test was approved for the adult market by the US FDA and in Europe and licensed for significant upfront money. In July 2023 AEZS expected it would sign a new North American deal based on its ...more  
Comment by prophetoffactzon Aug 14, 2024 7:22am

RE:wainwright does not follow cosciens

Perplexity Ai "HC Wainwright's last target price for Aeterna Zentaris was set at $15.00 on November 13, 2023." November 13, 2023 was about 1 month before the announcement of the ...more  
Post by lscfaon Aug 14, 2024 2:11am

wainwright does not follow cosciens

https://hcwco.com/services/research/coverage-universe/#healthcare
Post by prophetoffactzon Aug 13, 2024 3:34pm

Diagnostic

Could CSCI get a milestone payment for the pediatric diagnostic from existing licensees in the near future? How aggressivly have they marketed the product to date without the ability to sell to ...more  
Post by prophetoffactzon Aug 13, 2024 3:28pm

Assorted programs

"We are evaluating the data obtained to date and considering our plans for the treatment of NMOSD using an AIM Biologicals platform." "We are currently continuing in-vitro  ...more  
Post by prophetoffactzon Aug 13, 2024 3:23pm

Avenanthramide pill

"The Company expects to initiate the MAD arm during Q3, the summer 2024."
Post by prophetoffactzon Aug 13, 2024 3:16pm

Avenanthramide chewy

They've now got an avenanthramide chewy product for exercise inflammation, etc. The also mention they've demonstrated the yeast beta glucan in vitro and in vivo. Last November they said they ...more  
Comment by prophetoffactzon Aug 13, 2024 2:39pm

RE:RE:RE:RE:RE:New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

The merger wasn't completed until Jun. 6 or basically the end of the quarter. The TSX-V listing expenses will fall off. Human resources can be streamlined. They only need one CFO for instance ...more  
Post by lscfaon Aug 13, 2024 2:38pm

SGA history

The merged co. is distorting historical info by removing AEZS licensing fees and development services revenue from top line revenue and netting it against AEZS R&D and SG&A.     ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities